Abel Ang is the Group CEO of AMTH, a US$250M revenue global player in urology devices and services.

 

He served as the Senior Advisor to the CEO of Greatbatch Inc (NYSE: ITGR), providing guidance relative to the commercialization of medical device technologies in the cardiac, neurology, vascular, and orthopedics. 

 

Prior to Greatbatch, Ang was President, Asia/Pacific for Hill-Rom Inc. a US$3B revenue medical devices company (NYSE: HRC). He formerly served as the Chief Technology Officer for Hill-Rom Inc. He also held the position of VP and GM of Hill-Rom’s US$420M Global Surfaces Therapy Business unit.

 

Ang sits on the Board of Accelerate Technologies. In addition, he sits on the Boards of the following operating and investment companies: Dornier MedTech, AMT Pte Ltd and SonoMotion. He chairs the Board of AWAK Technologies. He was formerly on the Board and Nominating Committee of Aslan Pharmaceuticals (NYSE: ASLN).

 

Ang is an Adjunct Associate Professor at the Nanyang Business School and Waseda University, where he teaches in their respective MBA programs. Ang has a Master of Science in Computational Biology from Rutgers University. He attended Harvard Business School’s Advanced Management Program in 2012.